EOLS - Evolus, Inc.
32.94 0.00 (0.00%)
After hours: 4:43PM EDT
| Previous Close | 31.94 |
| Open | 32.00 |
| Bid | 28.34 x 800 |
| Ask | 32.80 x 1000 |
| Day's Range | 30.24 - 33.10 |
| 52 Week Range | 6.75 - 39.50 |
| Volume | 282,230 |
| Avg. Volume | 421,090 |
| Market Cap | 778.715M |
| Beta | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.38 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 30.50 |
- GlobeNewswire•8 hours ago
Clinical Overview of PrabotulinumtoxinA for the Investigational Treatment of Frown Lines to Be Featured During Summer Cosmetic Bootcamp 2018
Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the presentation of a comprehensive overview of the clinical program for its neuromodulator product candidate, DWP-450 (prabotulinumtoxinA), at the Summer Cosmetic Bootcamp taking place June 21-24, 2018 in Aspen, CO. The oral presentation “Toxin Update -- What We Have Now and What is Coming” will be delivered today during the Neurotoxin University module by Kenneth Beer, M.D., co-founder of the Cosmetic Bootcamp and voluntary Assistant Professor at the University of Miami. Dr. Beer will present top-line results of the Company’s three Phase III studies, all of which met their respective primary endpoints. This presentation expands on data presented at the American Academy of Dermatology (AAD) annual meeting in February 2018.
- GlobeNewswire•4 days ago
Evolus Expands Management Team with Appointment of Michael Mazen Jafar as Chief Marketing Officer
Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a company dedicated to aesthetic medicine, today announced the expansion of its management team with the appointment of Michael Mazen Jafar as Chief Marketing Officer. Mr. Jafar joins Evolus from Allergan where he most recently served as Vice President, Medical Aesthetics. At Allergan Mr. Jafar led the commercial launch of Juvederm Voluma®, which has been recognized as not only one of the largest launches in the medical aesthetics category, but also the most successful, as measured by year one sales.
- GlobeNewswire•8 days ago
Evolus to Participate in Two Upcoming Investor Conferences
IRVINE, Calif., June 14, 2018-- Evolus, Inc., a premiere aesthetics company, announced today that members of management will be participating in two upcoming investor conferences in New York, NY.. An audio ...
- Motley Fool•14 days ago
Why Nabors Industries, PolarityTE, and Evolus Slumped Today
Find out which of these stocks got criticism from a famous short-seller.
- GlobeNewswire•18 days ago
Evolus to Present at the Jefferies 2018 Global Healthcare Conference
IRVINE, Calif., June 04, 2018-- Evolus, Inc., a premiere aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, announced today that Lauren Silvernail, ...
- GlobeNewswire•24 days ago
Evolus Appoints Veteran Healthcare Executive Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development
Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a premiere aesthetics company, today announced the appointment of Lauren Silvernail as Chief Financial Officer and Executive Vice President, Corporate Development. Mrs. Silvernail joins Evolus from Revance Therapeutics where she most recently served as Chief Financial Officer and Chief Business Officer. Prior to her time at Revance Therapeutics, Mrs. Silvernail was Chief Financial Officer and Vice President, Corporate Development at ISTA Pharmaceuticals Inc. working to grow the business from development stage through commercialization and into profitability until its acquisition by Bausch + Lomb.
- Bloomberg•29 days ago
Rival to Botox Roars Back With 123% Rally Despite FDA Delay
Evolus Inc. is reaching new highs, shrugging off a delay of potential approval of its Botox-rivaling wrinkle treatment. Why so much optimism when a Food and Drug Administration regulatory decision on the company’s key product, DWP-450, was pushed back from a hoped-for summer verdict to spring 2019? Some of the enthusiasm may stem from the company’s new Chief Executive Officer, David Moatazedi.
- Reuters•last month
Evolus investors frown as FDA declines to approve Botox rival
U.S. health regulators on Wednesday declined to approve Evolus Inc's rival product to Allergan Plc's Botox, citing deficiencies related to the chemistry and manufacturing of its potential treatment for frown lines sending its shares down as much as 35 percent. The deficiencies that were communicated by the U.S. Food and Drug Administration in a so-called complete response letter were "manageable", according to CEO Moatazedi, who joined the company earlier this month after serving as U.S. head of Allergan's medical aesthetics business.
- Business Wire•last month
INVESTOR ALERT: Investigation on Behalf of Evolus Investors Announced by Holzer & Holzer
Holzer & Holzer, LLC is investigating whether Evolus, Inc. complied with the federal securities laws. On May 16, 2018, Evolus announced that the FDA sent a Complete Response Letter related to the Company’s Biologics License Application for DWP-450, a developmental treatment of frown lines.
- Motley Fool•last month
Why Evolus, Inc. Is Crashing Today
Shares swoon after the FDA gives the thumbs down to its lead compound. Here's what investors need to know.
- Benzinga•last month
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Biolinerx Ltd/S ADR (NASDAQ: BLRX ) stock was trading ...
- GlobeNewswire•last month
Evolus Announces Progress with DWP-450 Regulatory Submissions
Evolus, Inc. (EOLS) (“Evolus”), a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced updates related to the regulatory progress of its pending Biologics License Application (“BLA”) for DWP-450 (prabotulinumtoxinA) to the U.S. Food and Drug Administration (“FDA”). The FDA issued an Establishment Inspection Report (“EIR”) to Daewoong Pharmaceutical Co. Ltd. (“Daewoong”) confirming the favorable completion of its pre-approval inspection of Daewoong’s manufacturing facility in South Korea which was purpose built for production of DWP-450.
- GlobeNewswire•last month
Evolus to Provide Regulatory Update on Wednesday, May 16, 2018
IRVINE, Calif., May 16, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, announced today that the Company ...
- Benzinga•last month
Benzinga's Daily Biotech Pulse: Aytu Rallies On Earnings, Evolus Awaits FDA Verdict, BofA Conference Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 14) ABIOMED, Inc. (NASDAQ: ABMD ) Bio-Rad Laboratories, Inc. (NYSE: ...
- GlobeNewswire•last month
Evolus Reports First Quarter 2018 Financial Results
IRVINE, Calif., May 10, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results ...
- GlobeNewswire•2 months ago
Evolus Appoints Allergan Aesthetics Head as President and Chief Executive Officer
IRVINE, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- Evolus, Inc. (EOLS) (“Evolus” or the “Company”), a lifestyle aesthetics company, announced that its board of directors has named David Moatazedi as President and Chief Executive Officer. Mr. Moatazedi has nearly twenty years of commercial and executive experience building multiple market leading brands. David also led several acquisitions for Allergan, including LifeCell™ for $2.9B and ZELTIQ® Aesthetics for $2.5B.
- GlobeNewswire•2 months ago
Evolus to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
IRVINE, Calif., May 03, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced that Murthy Simhambhatla, ...
- GlobeNewswire•2 months ago
Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting
IRVINE, Calif., April 23, 2018-- Evolus, Inc., a lifestyle aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced it will present ...
- GlobeNewswire•3 months ago
Evolus Phase III European - Canadian Head-to-Head Trial of prabotulinumtoxinA Compared to Botox® Meets Primary Endpoint
IRVINE, Calif., April 05, 2018-- Evolus, Inc., a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today announced the presentation ...
- GlobeNewswire•3 months ago
Evolus Reports Fourth Quarter and Full Year 2017 Financial Results
IRVINE, Calif., March 29, 2018-- Evolus, Inc., a medical aesthetics company focused on delivering advanced aesthetic procedures and treatments to physicians and consumers, today reported financial results ...
- Simply Wall St.•4 months ago
Who Really Owns Evolus Inc (NASDAQ:EOLS)?
Today, I will be analyzing Evolus Inc’s (NASDAQ:EOLS) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure has been found to have an impact on shareholderRead More...
- PR Newswire•4 months ago
Evolus Announces Presentation of Phase III European - Canadian Comparative Data
IRVINE, Calif. , Feb. 17, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase III comparative clinical trial of its investigational prabotulinumtoxinA ...
- PR Newswire•4 months ago
Evolus Announces Presentation of Phase III Comparative Data of PrabotulinumtoxinA and OnabotulinumtoxinA
Trial Results to be Presented at American Academy of Dermatology Meeting IRVINE, Calif. , Feb. 16, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) today announced the presentation of data from the Phase ...
- PR Newswire•4 months ago
Evolus, Inc. Announces Closing of Initial Public Offering of Common Stock
IRVINE, Calif. , Feb. 12, 2018 /PRNewswire/ -- Evolus, Inc. (NASDAQ: EOLS) ("Evolus"), a medical aesthetics company focused on providing physicians and their patients with expanded choices in ...
